Liquidia Co. (NASDAQ:LQDA) Holdings Increased by Whitefort Capital Management LP

Whitefort Capital Management LP boosted its position in shares of Liquidia Co. (NASDAQ:LQDA - Free Report) by 16.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,987,245 shares of the company's stock after purchasing an additional 285,220 shares during the period. Liquidia makes up 11.2% of Whitefort Capital Management LP's portfolio, making the stock its 3rd biggest position. Whitefort Capital Management LP owned 2.35% of Liquidia worth $23,370,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in LQDA. Steward Partners Investment Advisory LLC acquired a new stake in Liquidia in the fourth quarter valued at $59,000. Summit Investment Advisors Inc. raised its stake in shares of Liquidia by 35.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company's stock valued at $78,000 after purchasing an additional 1,719 shares in the last quarter. D. E. Shaw & Co. Inc. bought a new position in shares of Liquidia during the fourth quarter worth about $142,000. EntryPoint Capital LLC bought a new position in shares of Liquidia during the fourth quarter worth about $154,000. Finally, Bayesian Capital Management LP acquired a new position in Liquidia in the fourth quarter worth about $163,000. Hedge funds and other institutional investors own 64.54% of the company's stock.

Insider Buying and Selling at Liquidia

In other news, insider Rajeev Saggar sold 2,450 shares of Liquidia stock in a transaction on Monday, April 21st. The stock was sold at an average price of $13.67, for a total transaction of $33,491.50. Following the transaction, the insider now directly owns 263,152 shares in the company, valued at approximately $3,597,287.84. This trade represents a 0.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Russell Schundler sold 5,964 shares of the company's stock in a transaction on Monday, April 14th. The shares were sold at an average price of $13.57, for a total value of $80,931.48. Following the completion of the sale, the general counsel now owns 570,301 shares of the company's stock, valued at approximately $7,738,984.57. This trade represents a 1.03% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 33,138 shares of company stock valued at $450,233. Company insiders own 26.50% of the company's stock.

Liquidia Trading Down 9.8%

NASDAQ LQDA opened at $17.03 on Tuesday. The company has a 50-day moving average price of $14.61 and a two-hundred day moving average price of $13.46. Liquidia Co. has a 52 week low of $8.26 and a 52 week high of $19.41. The stock has a market cap of $1.46 billion, a price-to-earnings ratio of -10.45 and a beta of 0.24.

Liquidia (NASDAQ:LQDA - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.03). The business had revenue of $3.12 million for the quarter, compared to the consensus estimate of $3.23 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. As a group, equities research analysts expect that Liquidia Co. will post -1.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have commented on the company. Scotiabank reaffirmed an "outperform" rating on shares of Liquidia in a report on Monday, May 5th. HC Wainwright reissued a "buy" rating and set a $29.00 price target on shares of Liquidia in a research report on Monday, May 12th. Raymond James lifted their price objective on shares of Liquidia from $27.00 to $29.00 and gave the stock a "strong-buy" rating in a report on Friday, May 9th. Oppenheimer lowered shares of Liquidia from a "market perform" rating to an "underperform" rating and set a $13.00 target price for the company. in a research note on Monday. Finally, Needham & Company LLC restated a "buy" rating and issued a $25.00 price target on shares of Liquidia in a research report on Monday, May 12th. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $25.56.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Want to see what other hedge funds are holding LQDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Liquidia Co. (NASDAQ:LQDA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.